HBS Capital ApS

HBS Capital ApS is a holding company established and ultimately owned by the Bøgh-Sørensen family. ​​The Group’s primary business activity is being an ambitious operator in the European market for pharmaceuticals​through the investment in Orifarm Group A/S, which is the largest supplier of parallel imported pharmaceuticals in Europe, and a producer and seller of well-known brands as well as generic pharmaceuticals. ​​Secondly the HBS Capital Group invests across a broad range of asset classes including Private Equity, Real Estate,​Investment cars and other financial assets both public and private, through the ownership of Habico Invest A/S. ​​Orifarm Group​Orifarm Group is a dynamic international player in the healthcare business. Our vision is to be no. 1 in making healthcare a better deal. Every day, we strive to make high quality pharmaceuticals at affordable prices available to end users by manufacturing, commercializing, and trading products. The Group's purpose is to provide as many people as possible with access to affordable quality medicine. ​​We supply a wide range of high-quality pharmaceuticals across several therapeutic areas and stages of illness. Our portfolio covers pharmaceuticals for primary as well as secondary care by specialists, over the counter (OTC), and consumer healthcare products. ​​It is our mission to challenge the market and make affordable, high-quality healthcare accessible. We want to create competition and provide important savings for society and to ensure better value for money for consumers while maintaining a high quality in our products. ​​Orifarm Group operates on three product platforms: ​​Pharma Trade​Import, re-packaging and sales of pharmaceuticals leveraging price arbitrages between countries; including medicines without a MA (marketing authorization) in a country (unlicensed) and comparator pharmaceuticals for clinical trials. ​​Specialty Rx​Off-patent, small molecule medicine sold via pharmacy substitution and hospital tendering (nGx) or prescribed by​physicians without substitution (pRx). ​​Consumer Healthcare​Products for health needs available without prescription; chosen by consumers; OTC regulated as pharmaceutical​with an API, while VMS is regulated as food supplements (no API). ​​Habico Invest ​Habico Invest A/S (“Habico Invest”) serves as the principal investment holding company for the Bøgh-Sørensen family. Habico Invest was established by Birgitte and Hans Bøgh-Sørensen, the founders of the wholly family-owned European pharmaceutical company Orifarm Group A/S. ​​Habico Invest operates across two distinct avenues: Operating businesses and investments. ​​​​ Our operating activities are concentrated in the curation and dealing of rare, investment-grade cars; fine wine investment and distribution (operating across B2B and B2C channels via Hans’ Wine Club); and the orchestration of bespoke events through Scuderia Faggio. ​​In our investment portfolio, we allocate long-term capital across both public and private markets. We invest across the capital structure, with exposure encompassing: ​​• Investment-grade and high-yield credit; ​• Listed equities; ​• Alternative funds (real-estate, infrastructure, private equity, private credit, and venture capital); ​• Direct minority investments in high-growth enterprises led by exceptional founder-management teams. ​​Anchored by a permanent capital base, Habico Invest can invest with a long-term investment horizon.